Gilead Sciences published new data Friday on its antiviral drug remdesivir that shows it reduced the risk of death for severely sick coronavirus patients by 62% compared with standard care alone. The findings are being presented at the Virtual Covid-19 Conference as part of the 23rd International AIDS Conference, the company said. Shares of Gilead rose almost 3% in premarket trading Friday on the news. The company said it collected the data from a comparative analysis using both patients in its phase three trial as well as patients from “a real-world retrospective cohort of patients.” Gilead said its findings warrant ... (full story)